United Therapeutics Corporation (UTHR)
Pre-market:
| Previous close | 238.26 |
| Open | 236.28 |
| Bid | 234.19 x 200 |
| Ask | 234.83 x 200 |
| Day's range | 233.31 - 237.71 |
| 52-week range | 204.44 - 261.54 |
| Volume | |
| Avg. volume | 481,744 |
| Market cap | 10.396B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 11.83 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 01, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023.
- Business Wire
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 26, 2024--Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo.
- Business Wire
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 24, 2024--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.
